Functional Validation of Drug Nanoconjugates in vivo
Pp. 184-198 (15)
Ibane Abasolo, Yolanda Fernández and Simó Schwartz
Preclinical development of nanotechnology formulated-drugs shares many
features with the development of other pharmaceutical products. However, there are
some relevant differences. Nanoparticulated therapeutic systems have challenges
related to their production, physicochemical characterization, stability and sterilization,
but offer special advantages regarding drug solubilization, bioavailability and
biodistribution. A good design of the nanoconjugate, should take into account these
pros and cons in the specific setting of the target disease. Moreover, researchers should
also bear these in mind when planning in vitro and in vivo proof-of-concept assays. In
this chapter we will focus in assays required to test the efficacy of a therapeutic
nanoconjugate and how appropriate animal models and imaging technologies help to
speed up preclinical development. In addition, we will also describe how basic in vivo
pharmacokinetic and biodistribution assays aid researchers to optimize the design of a
highly active and non-toxic nanoconjugate.
Animal models, In vivo preclinical validation, Nanomedicine,
Nanoconjugate, Optical bioluminescence and fluorescence imaging, Proof-ofconcept,
Toxicology, Whole-body biodistribution.
Functional Validation & Preclinical Research (FVPR). Drug Delivery & Targeting. CIBBIMNanomedicine. Vall d’Hebron Institut de Recerca (VHIR). Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN). Barcelona. Spain.